

LEMAITRE VASCULAR INC

Form 10-Q

November 03, 2017

[Table of Contents](#)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934**

For the quarterly period ended September 30, 2017

Or

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934**

For the transition period from _____ to _____.

Commission File Number 001-33092

LEMAITRE VASCULAR, INC.

(Exact name of registrant as specified in its charter)

| | |
|---|--|
| Delaware (State or other jurisdiction of | 04-2825458 (I.R.S. Employer |
| incorporation or organization) | Identification No.) |
| 63 Second Avenue, Burlington, Massachusetts (Address of principal executive offices) | 01803 (Zip Code) |
| (781) 221-2266 | |
| (Registrant's telephone number, including area code) | |

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company and emerging growth Company in Rule 12b-2 of the Exchange Act.

| | |
|---|---------------------------|
| Large accelerated filer | Accelerated filer |
| Non-accelerated filer (Do not check if a smaller reporting company) | Smaller reporting company |
| | Emerging growth company |

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The registrant had 19,264,940 shares of common stock, \$.01 par value per share, outstanding as of October 31, 2017.

Table of Contents

LEMAITRE VASCULAR

FORM 10-Q

TABLE OF CONTENTS

| | Page |
|---|------|
| Part I. Financial Information: | |
| Item 1. Financial Statements | |
| <u>Consolidated Balance Sheets as of September 30, 2017 (unaudited) and December 31, 2016</u> | 3 |
| <u>Unaudited Consolidated Statements of Operations for the three-month and nine-month periods ended September 30, 2017 and 2016</u> | 4 |
| <u>Unaudited Consolidated Statements of Comprehensive Income for the three-month and nine-month periods ended September 30, 2017 and 2016</u> | 5 |
| <u>Unaudited Consolidated Statements of Cash Flows for the three-month and nine-month periods ended September 30, 2017 and 2016</u> | 6 |
| <u>Notes to Unaudited Consolidated Financial Statements</u> | 7 |
| Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u> | 19 |
| Item 3. <u>Quantitative and Qualitative Disclosure about Market Risk</u> | 29 |
| Item 4. <u>Controls and Procedures</u> | 30 |
| Part II. Other Information: | |
| Item 1. <u>Legal Proceedings</u> | 30 |
| Item 1A. <u>Risk Factors</u> | 31 |
| Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u> | 31 |
| Item 6. <u>Exhibits</u> | 32 |
| <u>Signatures</u> | 33 |
| Index to Exhibits | |

Table of Contents**Part I. Financial Information****Item 1. Financial Statements****LeMaitre Vascular, Inc.****Consolidated Balance Sheets**

| | (unaudited) September 30, 2017 | December 31, 2016 |
|--|--|------------------------------|
| | (in thousands, except share data) | |
| Assets | | |
| Current assets: | | |
| Cash and cash equivalents | \$ 37,514 | \$ 24,288 |
| Accounts receivable, net of allowances of \$315 at September 30, 2017, and \$258 at December 31, 2016 | 13,553 | 13,191 |
| Inventory and other deferred costs | 21,095 | 19,578 |
| Prepaid expenses and other current assets | 3,480 | 1,970 |
| Total current assets | 75,642 | 59,027 |
| Property and equipment, net | 11,367 | 8,012 |
| Goodwill | 23,850 | 23,426 |
| Other intangibles, net | 8,669 | 9,897 |
| Deferred tax assets | 1,562 | 1,399 |
| Other assets | 179 | 163 |
| Total assets | \$ 121,269 | \$ 101,924 |
| Liabilities and stockholders equity | | |
| Current liabilities: | | |
| Accounts payable | \$ 1,617 | \$ 1,217 |
| Accrued expenses | 8,803 | 8,804 |
| Acquisition-related obligations | 1,690 | 461 |
| Total current liabilities | 12,110 | 10,482 |
| Deferred tax liabilities | 1,948 | 1,941 |
| Other long-term liabilities | 1,098 | 2,001 |
| Total liabilities | 15,156 | 14,424 |
| Stockholders equity: | | |
| Preferred stock, \$0.01 par value; authorized 3,000,000 shares; none outstanding | | |
| Common stock, \$0.01 par value; authorized 37,000,000 shares; issued 20,742,411 shares at September 30, 2017, and 20,040,348 shares at December 31, 2016 | 207 | 200 |

Edgar Filing: LEMAITRE VASCULAR INC - Form 10-Q

| | | |
|---|------------|------------|
| Additional paid-in capital | 92,685 | 85,378 |
| Retained earnings | 25,109 | 15,335 |
| Accumulated other comprehensive loss | (2,280) | (4,583) |
| Treasury stock, at cost; 1,480,101 shares at September 30, 2017 and 1,452,810 shares at December 31, 2016 | (9,608) | (8,830) |
| Total stockholders' equity | 106,113 | 87,500 |
| Total liabilities and stockholders' equity | \$ 121,269 | \$ 101,924 |

See accompanying notes to consolidated financial statements.

Table of Contents

LeMaitre Vascular, Inc.

Consolidated Statements of Operations

(unaudited)

| | Three months ended | | Nine months ended | |
|--|---------------------------------------|--------------------|--------------------|--------------------|
| | September 30, 2017 | September 30, 2016 | September 30, 2017 | September 30, 2016 |
| | (in thousands, except per share data) | | | |
| Net sales | \$ 24,822 | \$ 23,216 | \$ 74,714 | \$ 65,863 |
| Cost of sales | 7,245 | 6,197 | 22,269 | 19,121 |
| Gross profit | 17,577 | 17,019 | 52,445 | 46,742 |
| Sales and marketing | 6,201 | 6,541 | 19,754 | 19,353 |
| General and administrative | 4,562 | 3,595 | 12,857 | 10,343 |
| Research and development | 1,761 | 1,539 | 5,053 | 4,619 |
| Total operating expenses | 12,524 | 11,675 | 37,664 | 34,315 |
| Income from operations | 5,053 | 5,344 | 14,781 | 12,427 |
| Other income (expense): | | | | |
| Interest income | 48 | 24 | 100 | 55 |
| Foreign currency gain (loss) | (28) | (61) | (103) | (74) |
| Income before income taxes | 5,073 | 5,307 | 14,778 | 12,408 |
| Provision for income taxes | 31 | 2,078 | 1,885 | 4,415 |
| Net income | \$ 5,042 | \$ 3,229 | \$ 12,893 | \$ 7,993 |
| Earnings per share of common stock: | | | | |
| Basic | \$ 0.26 | \$ 0.17 | \$ 0.68 | \$ 0.43 |
| Diluted | \$ 0.25 | \$ 0.17 | \$ 0.65 | \$ 0.42 |
| Weighted-average shares outstanding: | | | | |
| Basic | 19,124 | 18,524 | 18,859 | 18,423 |
| Diluted | 20,147 | 19,248 | 19,970 | 19,103 |
| Cash dividends declared per common share | \$ 0.055 | \$ 0.045 | \$ 0.165 | \$ 0.135 |

See accompanying notes to consolidated financial statements.

Table of Contents

LeMaitre Vascular, Inc.
Consolidated Statements of Comprehensive Income
(unaudited)

| | Three months ended | | Nine months ended | |
|--|---------------------------|----------------------|--------------------------|----------------------|
| | September 30, | September 30, | September 30, | September 30, |
| | 2017 | 2016 | 2017 | 2016 |
| | (in thousands) | | | |
| Net income | \$ 5,042 | \$ 3,229 | \$ 12,893 | \$ 7,993 |
| Other comprehensive income (loss): | | | | |
| Foreign currency translation adjustment, net | 664 | 312 | 2,303 | 836 |
| Total other comprehensive income (loss) | 664 | 312 | 2,303 | 836 |
| Comprehensive income | \$ 5,706 | \$ 3,541 | \$ 15,196 | \$ 8,829 |

See accompanying notes to consolidated financial statements.

Table of Contents**LeMaitre Vascular, Inc.****Consolidated Statements of Cash Flows****(unaudited)**

| | For the nine months ended September 30, | |
|---|--|-------------|
| | 2017 | 2016 |
| | (in thousands) | |
| Operating activities | | |
| Net income | \$ 12,893 | \$ 7,993 |
| Adjustments to reconcile net income to net cash provided by operating activities: | | |
| Depreciation and amortization | 2,966 | 2,658 |
| Stock-based compensation | 1,845 | 1,195 |
| Provision for (recovery of) doubtful accounts | 152 | 52 |
| Provision for inventory write-downs | 272 | 280 |
| Foreign currency transaction loss | (34) | (1) |
| Changes in operating assets and liabilities: | | |
| Accounts receivable | (50) | (68) |
| Inventory and other deferred costs | (1,330) | (216) |
| Prepaid expenses and other assets | (1,403) | (390) |
| Accounts payable and other liabilities | 787 | 1,199 |
| Net cash provided by operating activities | 16,098 | 12,702 |
| Investing activities | | |
| Purchases of property and equipment and other assets | (4,780) | (1,830) |
| Payments related to acquisitions | | (2,368) |
| Net cash used in investing activities | (4,780) | (4,198) |
| Financing activities | | |
| Payments of deferred acquisition consideration | (427) | (249) |
| Proceeds from issuance of common stock | 5,470 | 1,384 |
| Purchase of treasury stock | (778) | (183) |
| Common stock cash dividend paid | (3,119) | (2,487) |
| Net cash provided by (used in) financing activities | 1,146 | (1,535) |
| Effect of exchange rate changes on cash and cash equivalents | 762 | 230 |
| Net increase in cash and cash equivalents | 13,226 | 7,199 |
| Cash and cash equivalents at beginning of period | 24,288 | 27,451 |
| Cash and cash equivalents at end of period | \$ 37,514 | \$ 34,650 |

Supplemental disclosures of cash flow information (see Note 11)

See accompanying notes to consolidated financial statements.

Table of Contents

LeMaitre Vascular, Inc.

Notes to Consolidated Financial Statements

September 30, 2017

(unaudited)

1. Organization and Basis for Presentation

Description of Business

Unless the context requires otherwise, references to LeMaitre Vascular, we, our, and us refer to LeMaitre Vascular, Inc. and our subsidiaries. We develop, manufacture, and market medical devices and implants used primarily in the field of vascular surgery. We also derive revenues from the processing and cryopreservation of human tissues for implantation in patients. We operate in a single segment in which our principal product lines include the following: valvulotomes, biologic vascular patches, balloon catheters, carotid shunts, biologic vascular grafts, anastomotic clips, radiopaque marking tape, vascular grafts, remote endarterectomy devices, laparoscopic cholecystectomy devices, angioscopes, and powered phlebectomy devices. Our offices are located in Burlington, Massachusetts; Fox River Grove, Illinois; Mississauga, Canada; Sulzbach, Germany; Milan, Italy; Madrid, Spain; North Melbourne, Australia; Tokyo, Japan; and Shanghai, China.

Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal, recurring adjustments considered necessary for a fair presentation of the results of these interim periods have been included. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Actual results may differ from these estimates. Our estimates and assumptions, including those related to bad debts, inventories, intangible assets, sales returns and discounts, share-based compensation, and income taxes are updated as appropriate. The results for the nine months ended September 30, 2017 are not necessarily indicative of results to be expected for the entire year. The information contained in these interim financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2016, including the notes thereto, included in our Form 10-K filed with the Securities and Exchange Commission (SEC) on March 9, 2017.

Consolidation

Our consolidated financial statements include the accounts of LeMaitre Vascular and the accounts of our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

Recent Accounting Pronouncements

In May 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2017-09 which provides guidance on determining which changes to the terms and conditions of share-based payment awards require an entity to apply modification accounting under ASC 718, Compensation – Stock Compensation. The new standard is effective for us beginning January 1, 2018, with early adoption permitted. The adoption of this standard is not expected to have a material impact on our financial statements.

In January 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2017-04, which, among other provisions, eliminates step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test will be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit's fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The new standard is effective for us beginning January 1, 2020, with early adoption permitted. The adoption of this standard is not expected to have a material impact on our financial statements.

Table of Contents

In January 2017, the FASB issued ASU 2017-01 which changes the definition of a business for purposes of determining whether a business has been acquired or sold. The amendment is intended to help companies evaluate whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new standard is effective for us beginning January 1, 2018, with early adoption permitted. The adoption of this standard is not expected to have a material impact on our financial statements.

In August 2016, the FASB issued ASU 2016-15, which changes the classification of certain cash receipts and cash payments within the statement of cash flows. The new standard is effective for us beginning January 1, 2018, with early adoption permitted. The adoption of this standard is not expected to have a material impact on our financial statements.

In May 2014, the FASB and the International Accounting Standards Board issued substantially converged final standards on revenue recognition. The FASB's ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), as amended from time to time, outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The new revenue recognition guidance becomes effective for us on January 1, 2018, with early adoption permitted on January 1, 2017. Entities have the option of using either a full retrospective or a modified approach to adopt the guidance in the ASU. Our assessment of the impact to our financial statements of adopting this standard is underway. We engaged external consultants to assist us with our analysis, which included evaluating our standard arrangements with customers, as well as arrangements specific to certain customer bases or product offerings, and reviewing a sample of actual contracts to determine whether there are additional attributes to consider beyond our standard arrangements. Although our assessment is not complete, we do not currently expect that adoption of Topic 606 will have a material impact on our consolidated financial statements. However, there will likely be changes to our revenue recognition accounting policy as well as other disclosures. Additionally, we have preliminarily determined that we will use the modified retrospective method of adoption.

2. Income Tax Expense

As part of the process of preparing our consolidated financial statements we are required to determine our income taxes in each of the jurisdictions in which we operate. This process involves estimating our actual current tax expense together with assessing temporary differences resulting from recognition of items for income tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included within our consolidated balance sheet. We must then assess the likelihood that our deferred tax assets will be recovered from taxable income during the carryback period or in the future; and to the extent we believe that recovery is not more likely than not, we must establish a valuation allowance. To the extent we establish a valuation allowance or increase this allowance in a period, we must reflect this increase as an expense within the tax provision in the statement of operations. We do not provide for income taxes on undistributed earnings of foreign subsidiaries, as our intention is to permanently reinvest these earnings.

We recognize, measure, present and disclose in our financial statements any uncertain tax positions that we have taken, or expect to take on a tax return. We operate in multiple taxing jurisdictions, both within and without the United States, and may be subject to audits from various tax authorities. Management's judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities, liabilities for uncertain tax positions, and any valuation allowance recorded against our net deferred tax assets. We will monitor the realizability of our deferred tax assets and adjust the valuation allowance accordingly.

Our policy is to classify interest and penalties related to unrecognized tax benefits as income tax expense.

Our 2017 income tax expense varies from the statutory rate mainly due to the generation of federal and state tax credits, permanent items and lower statutory rates from our foreign subsidiaries. Additionally, in the second and third quarters of 2017, we recognized certain discrete items primarily related to the exercise of stock options. Our 2016 income tax expense varied from the statutory rate mainly due to certain permanent items, offset by lower statutory rates from our foreign entities and a discrete item for stock option exercises.

Table of Contents

We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. As of September 30, 2017, the gross amount of unrecognized tax benefits exclusive of interest and penalties was \$451,000. We remain subject to examination until the statute of limitations expires for each respective tax jurisdiction. The statute of limitations will be open with respect to these tax positions until 2025. A reconciliation of beginning and ending amount of our unrecognized tax benefits is as follows:

| | Nine months ended September 30, 2017 (in thousands) |
|---|--|
| Unrecognized tax benefits as of December 31, 2016 | \$ 390 |
| Additions for tax positions of current year | 66 |
| Additions for tax positions of prior years | |
| Reductions for settlements with taxing authorities. | |
| Reductions for lapses of the applicable statutes of limitations | (5) |
| Unrecognized tax benefits as of September 30, 2017 | \$ 451 |

As of September 30, 2017, a summary of the tax years that remain subject to examination in our taxing jurisdictions is as follows:

| | |
|---------------|------------------|
| United States | 2014 and forward |
| Foreign | 2010 and forward |

3. Inventories and Other Deferred Costs

Inventories and other deferred costs consist of the following:

| | September 30, 2017 | December 31, 2016 |
|--|---------------------------|--------------------------|
| | (in thousands) | |
| Raw materials | \$ 3,657 | \$ 2,810 |
| Work-in-process | 3,491 | 2,489 |
| Finished products | 11,944 | 11,662 |
| Other deferred costs | 2,003 | 2,617 |
| Total inventory and other deferred costs | \$ 21,095 | \$ 19,578 |

We had inventory on consignment of \$1.3 million and \$1.1 million at September 30, 2017 and December 31, 2016, respectively.

In connection with our recent acquisition of the RestoreFlow allograft business, other deferred costs include costs incurred for the preservation of human vascular tissue available for shipment, tissue currently in active processing, and tissue held in quarantine pending release to implantable status. By federal law, human tissue cannot be bought or sold. Therefore, the tissues we preserve are not held as inventory, and the costs we incur to procure and process vascular tissue are instead accumulated and deferred.

4. Acquisition and Divestitures

Our strategy for growing our business includes the acquisition of complementary product lines and businesses. Our acquisitions, including those discussed below, have historically been made at prices above the fair value of the acquired identifiable assets, resulting in goodwill, due to expectations of synergies that will be realized by combining businesses. These synergies include the use of our existing sales channel to expand sales of the acquired businesses products and services, consolidation of manufacturing facilities, and the leveraging of our existing administrative infrastructure.

Table of Contents

The fair market valuations associated with these transactions fall within Level 3 of the fair value hierarchy, due to the use of significant unobservable inputs to determine fair value. The fair value measurements were calculated using unobservable inputs, primarily using the income approach, specifically the discounted cash flow method. The amount and timing of future cash flows within our analysis was based on our due diligence models, most recent operational budgets, long range strategic plans and other estimates.

RestoreFlow Allografts

On November 10, 2016, we entered into an agreement to acquire the assets of Restore Flow Allografts, LLC, a provider of human vascular tissue processing and cryopreservation services, for an initial purchase price of \$12 million, with additional payments of up to \$6 million, depending upon the satisfaction of certain contingencies. A payment of \$2 million is due not later than 15 days following the expiration of the 18 month period following the closing date, subject to reductions as specified in the agreement for each calendar month that certain retained employees are not employed by us due to resignation without good reason, or termination for cause, both as defined in the agreement. The portion of this payment that will be paid to retained employees and that is contingent on their continuing employment, approximately \$0.9 million, is being accounted for as post-combination compensation expense rather than purchase consideration. There are also two potential earn-outs under the agreement. The first earn-out is calculated at 50% of the amount by which net revenue in the first 12 months following the closing exceeds \$6 million, with such payout not to exceed \$2 million. The second earn-out is calculated at 50% of the amount by which net revenue in the second 12 months following the closing exceeds \$9 million, with such payout not to exceed \$2 million.

The RestoreFlow business derives revenue from human tissue preservation services, in particular the processing and cryopreservation of veins and arteries. By federal law, human tissues cannot be bought or sold. Therefore, the tissues we obtain and preserve are not held as inventory, and the costs we incur to procure and process vascular tissues are instead accumulated and deferred. Revenues are recognized for the provision of cryopreservation services rather than product sales.

The acquired assets included intellectual property, permits and approvals, data and records, equipment and furnishings, accounts receivable, inventory, literature, and customer and supplier information. We also assumed certain accounts payable. We accounted for the acquisition as a business combination.

The following table summarizes the preliminary purchase price allocation as of September 30, 2017:

| | Allocated Fair Value (in thousands) |
|---------------------------------|---|
| Accounts receivable | \$ 394 |
| Deferred cryopreservation costs | 2,583 |
| Equipment and supplies | 125 |
| Accounts payable | (286) |
| Intangible assets | 4,544 |
| Goodwill | 5,599 |
| Purchase price | \$ 12,959 |

Table of Contents

The goodwill is deductible for tax purposes over 15 years.

The following table reflects the preliminary allocation of the acquired intangible assets and related estimated useful lives:

| | Allocated Fair Value (in thousands) | Weighted Average Useful Life |
|-------------------------|---|---|
| Non-compete agreement | \$ 180 | 5.0 years |
| Tradename | 271 | 9.0 years |
| Procurement contracts | 617 | 9.0 years |
| Technology | 2,793 | 10.5 years |
| Customer relationships | 683 | 12.5 years |
| Total intangible assets | \$ 4,544 | |

The weighted-average amortization period of the acquired intangible assets was 10.3 years.

ProCol Biologic Graft

On March 18, 2016, we acquired the ProCol biologic vascular graft (ProCol) business for \$2.7 million from Hancock Jaffe Laboratories, Inc. (HJL) and CryoLife, Inc. (CRY). HJL was the owner and manufacturer of ProCol and CRY was the exclusive distributor of the ProCol graft. CRY also owned an option to purchase the ProCol business, which we acquired from CRY. We bought finished goods inventory and other ProCol related assets from CRY for \$2.0 million, which was paid in full at closing. We bought other ProCol assets from HJL for \$0.7 million, 50% of which was paid at closing, 25% of which was paid in the quarter ended September 30, 2016 and the remaining 25% of which was paid in the quarter ended March 31, 2017. Additional consideration is payable to HJL for a three-year period following the closing, calculated at 10% of ProCol revenues. This additional consideration was initially valued at \$0.3 million and will be re-measured each reporting period until the payment requirement ends, with any adjustments reported in income from operations. For the nine months ended September 30, 2017, the amount of the adjustment was not material to our financial statements.

Assets acquired included inventory, intellectual property and a related license, the ProCol trade name, customer lists, non-compete agreements and certain equipment and supplies. We did not assume any liabilities. We accounted for the acquisition as a business combination. The purchase accounting is complete.

The following table summarizes the purchase price allocation as of the acquisition date:

| | Allocated Fair Value (in thousands) |
|--------------------------------------|---|
| Inventory | \$ 2,080 |
| Manufacturing equipment and supplies | 25 |

| | |
|-------------------|----------|
| Intangible assets | 620 |
| Goodwill | 318 |
| Purchase price | \$ 3,043 |

The goodwill is deductible for tax purposes over 15 years.

Table of Contents

The following table reflects the allocation of the acquired intangible assets and related estimated useful lives:

| | Allocated Fair Value (in thousands) | Weighted Average Useful Life |
|--------------------------------|---|---|
| Non-compete agreement | \$ 84 | 5.0 years |
| Tradename | 109 | 9.5 years |
| Intellectual property | 277 | 9.0 years |
| Customer relationships | 150 | 9.0 years |
| Total intangible assets | \$ 620 | |

The weighted-average amortization period of the acquired intangible assets was 8.6 years.

Tru-Incise Valvulotome

In May 2015, we entered into an asset purchase agreement with UreSil, LLC (UreSil) to acquire the production and distribution rights of UreSil's Tru-Incise valvulotome for sales outside the United States for a purchase price of approximately \$1.4 million. We paid \$1.1 million at the closing with the remaining \$0.3 million paid at various points in 2016 and 2017. We accounted for the acquisition as a business combination. Assets acquired included inventory and intellectual property. We did not assume any liabilities. The purchase accounting is complete.

The following table summarizes the purchase price allocation at the date of the acquisition:

| | Allocated Fair Value (in thousands) |
|--------------------|---|
| Inventory | \$ 88 |
| Intangible assets | 545 |
| Goodwill | 742 |
| Purchase price | \$ 1,375 |

The goodwill is deductible for tax purposes over 15 years.

The following table reflects the allocation of the acquired intangible assets and related estimated useful lives:

| | Allocated Fair Value (in thousands) | Weighted Average Useful Life |
|--|---|---|
|--|---|---|

Edgar Filing: LEMAITRE VASCULAR INC - Form 10-Q

| | | | |
|-------------------------|----|-----|-----------|
| Non-compete agreement | \$ | 120 | 5.0 years |
| Tradename license | | 17 | 3.0 years |
| Product technology | | 391 | 7.0 years |
| Customer relationships | | 17 | 3.0 years |
| Total intangible assets | \$ | 545 | |

Table of Contents**5. Goodwill and Other Intangibles**

Goodwill consists of the following as of September 30, 2017:

| | |
|---------------------------------|----------------|
| | (in thousands) |
| Balance at December 31, 2016 | \$ 23,426 |
| Purchase accounting adjustments | 257 |
| Effects of currency exchange | 167 |
| Balance at September 30, 2017 | \$ 23,850 |

Other intangible assets consist of the following:

| | September 30, 2017 | | | December 31, 2016 | | |
|--------------------------------------|----------------------------|-----------------------------|--------------------------|----------------------------|-----------------------------|--------------------------|
| | Gross Carrying Value | Accumulated Amortization | Net Carrying Value | Gross Carrying Value | Accumulated Amortization | Net Carrying Value |
| | (in thousands) | | | | | |
| Product technology | \$ 10,271 | \$ 4,694 | \$ 5,577 | \$ 10,173 | \$ 4,017 | \$ 6,156 |
| Trademarks and licenses | 1,949 | 1,445 | 504 | 1,939 | 1,359 | 580 |
| Customer relationships | 5,372 | 3,142 | 2,230 | 5,216 | 2,588 | 2,628 |
| Other intangible assets | 1,574 | 1,216 | 358 | 1,558 | 1,025 | 533 |
| Total identifiable intangible assets | \$ 19,166 | \$ 10,497 | \$ 8,669 | \$ 18,886 | \$ 8,989 | \$ 9,897 |

These intangible assets are being amortized over their useful lives ranging from 1 to 13 years. The weighted-average amortization period for these intangibles as of September 30, 2017 is 9.1 years. Amortization expense is included in general and administrative expense and is as follows:

| | Three months ended | | Nine months ended | |
|----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| | September 30, 2017 | September 30, 2016 | September 30, 2017 | September 30, 2016 |
| | (in thousands) | | | |
| Amortization expense | \$ 443 | \$ 385 | \$ 1,353 | \$ 1,170 |

Table of Contents**6. Accrued Expenses and Other Long-term Liabilities**

Accrued expenses consist of the following:

| | September 30, 2017 | December 31, 2016 |
|--------------------------------|--------------------|-------------------|
| | (in thousands) | |
| Compensation and related taxes | \$ 5,715 | \$ 6,124 |
| Income and other taxes | 544 | 312 |
| Professional fees | 43 | 122 |
| Other | 2,501 | 2,246 |
| Total | \$ 8,803 | \$ 8,804 |

Other long-term liabilities consist of the following:

| | September 30, 2017 | December 31, 2016 |
|---------------------------------|--------------------|-------------------|
| | (in thousands) | |
| Acquisition-related liabilities | \$ 159 | \$ 1,253 |
| Deferred rent | 534 | 394 |
| Income taxes | 208 | 200 |
| Other | 197 | 154 |
| Total | \$ 1,098 | \$ 2,001 |

7. Segment and Enterprise-Wide Disclosures

Under Accounting Standards Codification Topic 280, *Segment Reporting*, operating segments are defined as components of an enterprise for which separate, discrete financial information is available and evaluated by the chief operating decision-maker in making decisions on how to allocate resources and assess performance. We view our operations and manage our business as one operating segment. No discrete operating information is prepared by us except for sales by product line and by legal entity for local reporting purposes.

Most of our revenues are generated in the United States, Germany, and other European countries as well as in Canada, Japan and China. Substantially all of our assets are located in the United States. Net sales to unaffiliated customers by country were as follows:

| | Three months ended | | Nine months ended | |
|---------------|-----------------------|-----------------------|-----------------------|-----------------------|
| | September 30, 2017 | September 30, 2016 | September 30, 2017 | September 30, 2016 |
| | (in thousands) | | | |
| United States | \$ 14,506 | \$ 13,718 | \$ 43,485 | \$ 37,180 |

Edgar Filing: LEMAITRE VASCULAR INC - Form 10-Q

| | | | | |
|-----------------|-----------|-----------|-----------|-----------|
| Germany | 2,885 | 2,651 | 8,624 | 7,920 |
| Other countries | 7,431 | 6,847 | 22,605 | 20,763 |
| Net Sales | \$ 24,822 | \$ 23,216 | \$ 74,714 | \$ 65,863 |

Table of Contents**8. Share-based Compensation**

Our Third Amended and Restated 2006 Stock Option and Incentive Plan allows for granting of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, unrestricted stock awards and deferred stock awards to our officers, employees, directors and consultants.

The components of share-based compensation expense were as follows:

| | Three months ended | | Nine months ended | |
|---------------------------------------|--------------------|--------------------|--------------------|--------------------|
| | September 30, 2017 | September 30, 2016 | September 30, 2017 | September 30, 2016 |
| | (in thousands) | | | |
| Stock option awards | \$ 723 | \$ 354 | \$ 1,347 | \$ 809 |
| Restricted stock units | 164 | 179 | 498 | 386 |
| Total share-based compensation | \$ 887 | \$ 533 | \$ 1,845 | \$ 1,195 |

Stock-based compensation is included in our statements of operations as follows:

| | Three months ended | | Nine months ended | |
|---------------------------------------|--------------------|--------------------|--------------------|--------------------|
| | September 30, 2017 | September 30, 2016 | September 30, 2017 | September 30, 2016 |
| | (in thousands) | | | |
| Cost of sales | \$ 46 | \$ 46 | \$ 141 | \$ 117 |
| Sales and marketing | 78 | 129 | 309 | 271 |
| General and administrative | 718 | 314 | 1,261 | 708 |
| Research and development | 45 | 44 | 134 | 99 |
| Total stock-based compensation | \$ 887 | \$ 533 | \$ 1,845 | \$ 1,195 |

Included in stock-based compensation expense for the three and nine months ended September 30, 2017 is a stock option modification charge of \$0.5 million for awards that are being allowed to continue to vest for approximately one year beyond the requisite service period associated with the recent departure of our President of International Operations. This expense is included in the caption General and administrative above.

Options granted during the nine months ended September 30, 2017 were not material. During the nine months ended September 30, 2016, we granted options to purchase 511,000 shares of our stock to employees and non-employee directors. We computed the weighted average fair values of employee stock options for option grants issued during the nine months ended September 30, 2016 using the Black-Scholes option model with the following assumptions:

| | |
|----------------|-------------|
| | 2016 |
| Dividend yield | 1.3% |

Edgar Filing: LEMAITRE VASCULAR INC - Form 10-Q

| | |
|--|---------|
| Volatility | 34.5% |
| Risk-free interest rate | 1.2% |
| Weighted average expected option term (in years) | 5.5 |
| Weighted average fair value per share of options granted | \$ 4.04 |

Restricted stock awards during the nine months ended September 30, 2017 were not material. During the nine months ended September 30, 2016 we awarded restricted stock units of 126,000 to employees. The weighted-average fair value per share of restricted stock unit awards issued for the nine months ended September 30, 2016 was \$14.11.

Table of Contents

We issued approximately 702,000 and 285,000 shares of common stock following the exercise or vesting of underlying stock options or restricted stock units in the nine months ended September 30, 2017 and 2016, respectively.

9. Net Income per Share

The computation of basic and diluted net income per share was as follows:

| | Three months ended September 30, | | Nine months ended September 30, | |
|--|---|-------------|--|-------------|
| | 2017 | 2016 | 2017 | 2016 |
| | (in thousands, except per share data) | | | |
| Basic: | | | | |
| Net income available for common stockholders | \$ 5,042 | \$ 3,229 | \$ 12,893 | \$ 7,993 |
| Weighted average shares outstanding | 19,124 | 18,524 | 18,859 | 18,423 |
| Basic earnings per share | \$ 0.26 | \$ 0.17 | \$ 0.68 | \$ 0.43 |
| Diluted: | | | | |
| Net income available for common stockholders | \$ 5,042 | \$ 3,229 | \$ 12,893 | \$ 7,993 |
| Weighted-average shares outstanding | 19,124 | 18,524 | 18,859 | 18,423 |
| Common stock equivalents, if dilutive | 1,023 | 724 | 1,111 | 680 |
| Shares used in computing diluted earnings per common share | 20,147 | 19,248 | 19,970 | 19,103 |
| Diluted earnings per share | \$ 0.25 | \$ 0.17 | \$ 0.65 | \$ 0.42 |
| Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive | | 426 | 1 | 143 |

10. Stockholders Equity
Share Repurchase Program

On July 25, 2016, our Board of Directors approved a stock repurchase program under which the Company was authorized to repurchase up to \$5 million of its common stock through transactions on the open market, in privately negotiated purchases or otherwise. This program expired on July 25, 2017. We did not make any repurchases under this program prior to its expiration.

On July 25, 2017, our Board of Directors approved a stock repurchase program under which the Company is authorized to repurchase up to \$7.5 million of its common stock through transactions on the open market, in privately negotiated purchases or otherwise. This program may be suspended or discontinued at any time, and expires on the earlier of July 25, 2018 or when the \$7.5 million repurchase limit is reached, unless extended by our Board of Directors. To date, we have not made any repurchases under this program.

Table of Contents**Dividends**

In February 2011, our Board of Directors approved a policy for the payment of quarterly cash dividends on our common stock. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by our Board of Directors on a quarterly basis. The dividend activity for the periods presented is as follows:

| Record Date | Payment Date | Per Share Amount Dividend Payment | |
|-------------------------|---------------------|--|----------------|
| | | | (in thousands) |
| Fiscal Year 2017 | | | |
| March 22, 2017 | April 6, 2017 | \$ 0.055 | \$ 1,029 |
| May 24, 2017 | June 8, 2017 | \$ 0.055 | \$ 1,036 |
| August 23, 2017 | September 6, 2017 | \$ 0.055 | \$ 1,055 |
| Fiscal Year 2016 | | | |
| March 21, 2016 | April 4, 2016 | \$ 0.045 | \$ 825 |
| May 25, 2016 | June 8, 2016 | \$ 0.045 | \$ 829 |
| August 22, 2016 | September 2, 2016 | \$ 0.045 | \$ 833 |
| November 21, 2016 | December 5, 2016 | \$ 0.045 | \$ 836 |

On October 24, 2017 our Board of Directors approved a quarterly cash dividend on our common stock of \$0.055 per share payable on December 7, 2017 to stockholders of record at the close of business on November 22, 2017, which will total approximately \$1.1 million.

11. Supplemental Cash Flow Information

| | Nine months ended | |
|---|---------------------------|---------------------------|
| | September 30, 2017 | September 30, 2016 |
| | (in thousands) | |
| Cash paid for income taxes, net | \$ 2,953 | \$ 2,809 |
| Shares withheld to satisfy RSU tax withholdings | \$ 778 | \$ 183 |

12. Fair Value Measurements

The fair value accounting guidance requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

Level 1 Quoted prices in active markets for identical assets or liabilities.

Level 2 Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.

As of September 30, 2017, we had cash equivalents in a money market fund that was valued using Level 1 inputs (quoted market prices for identical assets) at a fair value of \$19.0 million.

We had no Level 2 assets being measured at fair value on a recurring basis as of September 30, 2017.

As discussed in Note 4, we have contingent liabilities related to certain of our acquired businesses. These liabilities are or have been remeasured each reporting period using Level 3 techniques to assess the probability that we will be required to make future payments, and to estimate the amount of those payments. During the nine months ended September 30, 2017 we made fair-value adjustments to our contingent liabilities of \$0.6 million.

Table of Contents**13. Accumulated Other Comprehensive Loss**

| | Nine months ended | |
|--|--------------------------|-------------|
| | September 30, | |
| | 2017 | 2016 |
| | (in thousands) | |
| Beginning balance | \$ (4,583) | \$ (4,049) |
| Other comprehensive income (loss) before reclassifications | 2,303 | 836 |
| Amounts reclassified from accumulated other comprehensive loss | | |
| Ending Balance | \$ (2,280) | \$ (3,213) |

Changes to our accumulated other comprehensive loss consisted of foreign currency translation for the nine months ended September 30, 2017 and 2016.

Table of Contents**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

This Quarterly Report on Form 10-Q contains forward-looking statements (within the meaning of the federal securities law) that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this report regarding our strategy, future operations, future financial position, future net sales, projected costs, projected expenses, prospects and plans and objectives of management are forward-looking statements. The words anticipates, believes, estimates, expects, intends, may, plans, projects, will, would, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that the expectations underlying any of our forward-looking statements are reasonable, these expectations may prove to be incorrect, and all of these statements are subject to risks and uncertainties. Should one or more of these risks and uncertainties materialize, or should underlying assumptions, projections, or expectations prove incorrect, our actual results, performance, or financial condition may vary materially and adversely from those anticipated, estimated, or expected. These risks and uncertainties include, but are not limited to: the risk that the Company may not realize the anticipated benefits of its strategic activities; risks related to the integration of acquisition targets; the risk that assumptions about the market for the Company's products and the productivity of the Company's direct sales force and distributors may not be correct; risks related to product demand and market acceptance of the Company's products; risks associated with our newly acquired tissue processing and preservation operations and the related services we now provide; risks related to attracting, training and retaining sales representatives and other employees in new markets; adverse or fluctuating conditions in the general domestic and global economic markets; and the risk that the Company is not successful in transitioning to a direct-selling model in new territories.

Forward-looking statements reflect management's analysis as of the date of this quarterly report. Further information on potential risk factors that could affect our business and financial results is detailed in Part II, Item 1A, Risk Factors in this Quarterly Report on Form 10-Q and in our other filings with the Securities and Exchange Commission, including under the section headed Risk Factors in our most recent Annual Report on Form 10-K. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. The following discussion and analysis should be read in conjunction with our consolidated financial statements and the related notes included in this report and our other SEC filings, including our audited consolidated financial statements and the related notes contained in our Annual Report on Form 10-K for the year ended December 31, 2016, as filed with the SEC on March 8, 2017. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Unless the context indicates otherwise, references to LeMaitre Vascular, we, our, and us in this Quarterly Report on Form 10-Q refer to LeMaitre Vascular, Inc. and its subsidiaries.

LeMaitre, AnastoClip, Omniflow, ProCol, RestoreFlow and XenoSure are registered trademarks of LeMaitre Vascular or one of its subsidiaries. This Quarterly Report on Form 10-Q also includes the registered and unregistered trademarks of other persons, which are the property of their respective owners.

Overview

We are a medical device company that develops, manufactures, and markets medical devices and implants for the treatment of peripheral vascular disease. We also provide processing and cryopreservation services of human tissue for implantation into patients. Our principal product offerings are sold throughout the world, primarily in North America, Europe and, to a lesser extent, Asia and the Pacific Rim. We estimate that the annual worldwide market for all peripheral vascular devices approximates \$5 billion, within which our product lines address roughly \$870 million.

We have grown our business by using a three-pronged strategy: 1) pursuing a focused call point, 2) competing for sales of low-rivalry niche products, and 3) expanding our worldwide direct sales force while acquiring and developing complementary vascular devices. We have used acquisitions as a primary means of further accessing the larger peripheral vascular device market, and we expect to pursue this strategy in the future. Additionally, we have continued our efforts to expand our vascular device offerings through research and development. We currently manufacture most of our product lines at our Burlington, Massachusetts headquarters.

Table of Contents

Our products and services are used primarily by vascular surgeons who treat peripheral vascular disease through both open surgical methods and endovascular techniques. In contrast to interventional cardiologists and interventional radiologists, neither of whom are certified to perform open surgical procedures, vascular surgeons can perform both open surgical and minimally invasive endovascular procedures, and are therefore uniquely positioned to provide a wider range of treatment options.

Our principal product lines include the following: anastomotic clips, angioscopes, balloon catheters, biologic vascular grafts, biologic vascular patches, carotid shunts, laparoscopic cholecystectomy devices, powered phlebectomy devices, radiopaque marking tape, remote endarterectomy devices, synthetic vascular grafts, and valvulotomes. With the November 10, 2016 acquisition of the RestoreFlow allografts business, we also provide services related to the processing and cryopreservation of human vascular tissue.

To assist us in evaluating our business strategies, we regularly monitor long-term technology trends in the peripheral vascular device market. Additionally, we consider the information obtained from discussions with the medical community in connection with the demand for our products, including potential new product launches. We also use this information to help determine our competitive position in the peripheral vascular device market and our manufacturing capacity requirements.

Our business opportunities include the following:

the long-term growth of our direct sales force in North America, Europe, Asia and the Pacific Rim;

the addition of complementary products through acquisitions;

the updating of existing products and introduction of new products through research and development;

the introduction of our products in new territories upon receipt of regulatory approvals or registrations in these territories; and

the consolidation of, and automation of, product manufacturing at our facilities in our Burlington, Massachusetts corporate headquarters.

We sell our products and services primarily through a direct sales force. As of September 30, 2017 our sales force was comprised of 89 sales representatives in North America, Europe, Japan, China and Australia. We also sell our products in other countries through distributors. Our worldwide headquarters is located in Burlington, Massachusetts. Our international operations are headquartered in Sulzbach, Germany. We also have sales offices located in Tokyo, Japan; Mississauga, Canada; Madrid, Spain; Milan, Italy; Shanghai, China; and North Melbourne, Australia, and we have processing facilities in Fox River Grove, Illinois and North Melbourne, Australia. During the nine month periods ended September 30, 2017 and 2016, approximately 93% and 92%, respectively, of our net sales were generated in territories in which we employ direct sales representatives.

Historically, we have experienced success in lower-rivalry niche product segments, for example the market segments for biologic vascular patches and valvulotomes. In the biologic vascular patch market the number of competitors is

limited, and we believe that we have been able to increase segment share and increase selling prices, mainly due to the strength of our sales force. In the valvulotome market, we have been able to increase our selling prices while maintaining our unit market share. In contrast, we have experienced less success in highly competitive markets such as laparoscopic cholecystectomy catheters and synthetic grafts, where we face stronger competition from larger companies with greater resources and lower production costs. While we believe that these challenging market dynamics can be mitigated by our relationships with vascular surgeons, there can be no assurance that we will be successful in these highly competitive markets.

We have also experienced success in international markets, such as Europe, where we sometimes offer comparatively lower average selling prices. If we continue to seek growth opportunities outside of the North America, we will likely experience downward pressure on our gross margin.

Because we believe that direct-to-hospital sales engender closer customer relationships, and allow for higher selling prices and gross margins, we periodically enter into transactions with our distributors to transition their sales of our medical devices to our direct sales organization:

During 2015, we entered into definitive agreements with seven former UreSil, LLC distributors in Europe in order to terminate their distribution of our Tru-Incise valvulotome and we began selling direct-to-hospital in those geographies. The total of these termination fees was approximately \$0.2 million

Table of Contents

In August 2015, we entered into a definitive agreement with Grex Medical Oy (Grex), our distributor in Finland, in order to terminate their distribution of our products and we began selling direct-to-hospital in Finland as of January 1, 2016. The termination fee was approximately \$0.2 million.

We anticipate that the expansion of our direct sales organization in China will result in increased sales, marketing and regulatory expenses during 2017. As of September 30, 2017 we had seven employees in China.

Our strategy for growing our business includes the acquisition of complementary product lines and companies and occasionally the discontinuance or divestiture of products or activities that are no longer complementary:

In May 2015, we acquired the production and distribution rights of UreSil LLC's Tru-Incise valvulotome for sales outside of the United States for \$1.4 million.

In July 2015, we entered into an asset sales agreement with Merit Medical Ireland Limited to sell our inventory, intellectual property and customer lists associated with The UnBalloon, our non-occlusive modeling catheter product line for \$0.4 million.

In December 2015, we terminated our InvisiGrip vein stripper product line, and wrote down \$0.1 million of related inventory in Q3 2015.

In March 2016, we acquired substantially all of the assets as well as the production and distribution rights of the ProCol business from Hancock Jaffe Laboratories and CryoLife, Inc. for \$2.7 million plus 10% of net sales for three years following the closing. ProCol is a biologic vascular graft used for dialysis access, and is approved for sale in the United States.

In November 2016, we acquired substantially all of the assets related to the peripheral vascular allograft operations of Restore Flow Allografts, LLC for \$12.0 million plus additional payments of up to \$6 million, depending upon the satisfaction of certain contingencies.

In addition to relying upon acquisitions to grow our business, we also rely on our product development efforts to bring differentiated and next-generation products to market. These efforts have led to the following recent product developments:

In December 2015, we launched the 15-cm AnastoClip AC.

In October 2016, we launched additional sizes of our XenoSure patch.

In December 2016, we launched the 7.0mm diameter Omniflow II graft.

In October 2017, we launched XenoSure pledgets.

In addition to our sales growth strategies, we have also executed several operational initiatives designed to consolidate and streamline manufacturing within our Burlington facility. We expect these plant consolidations will result in improved production control, as well as reduced costs over the long-term. Our most recent manufacturing transitions included:

In March 2015, we initiated a project to transfer the manufacturing of the newly acquired angioscope product line to our Burlington facility. We had been purchasing the devices from Applied Medical since the September 2014 acquisition and completed the transition of manufacturing to our Burlington facility in December 2015.

In May 2015, we initiated a project to transfer the manufacturing of the newly acquired Tru-Incise valvulotome product line to our Burlington facility. We have been purchasing the devices from UreSil, LLC since the acquisition. We completed this transition in the first half of 2017.

In March 2016, we initiated a project to transfer the manufacturing of the newly acquired ProCol biologic product line to our Burlington facility. We have an agreement to purchase the product from Hancock Jaffe Laboratories for up to three years following the closing. We initiated the transfer of the production line and transition of manufacturing in 2016, and we expect the transfer to be complete in 2018, subject to regulatory approval.

Table of Contents

In the fourth quarter of 2017, we expect to complete the renovation of our Burlington facility, where we expect several of our biologic offerings, including the XenoSure patch and the ProCol biologic graft, will be produced or processed. We believe the cost of the facility renovation will be approximately \$2.3 million, of which approximately \$1.8 million has been incurred through September 30, 2017.

Our execution of these business opportunities may affect the comparability of our financial results from period to period and may cause substantial fluctuations from period to period as we incur related process engineering and other charges, as well as longer term impacts to revenues and operating expenditures.

Fluctuations in the rate of exchange between the U.S. dollar and foreign currencies, primarily the Euro, affect our financial results. For the nine months ended September 30, 2017, approximately 42% of our sales were to customers located outside the United States. We expect that foreign currencies will continue to represent a significant percentage of our future sales. Selling, marketing, and administrative costs related to these sales are largely denominated in the local currency, thereby partially mitigating our exposure to exchange rate fluctuations. However, as most of our foreign sales are denominated in local currency, if there is a decrease in the rate at which a foreign currency is exchanged for U.S. dollars, it will require more of the foreign currency to equal a specified amount of U.S. dollars. In such cases we will record less revenue in U.S. dollars than we did prior to the rate increase. For the nine months ended September 30, 2017, the effects of changes in foreign exchange rates decreased our reported sales by approximately \$0.3 million.

Net Sales and Expense Components

The following is a description of the primary components of our net sales and expenses:

Net sales. We derive our net sales from the sale of our products and services, less discounts and returns. Net sales include the shipping and handling fees paid for by our customers. Most of our sales are generated by our direct sales force and are shipped and billed to hospitals or clinics throughout the world. In countries where we do not have a direct sales force, sales are primarily to distributors, who in turn sell to hospitals and clinics. In certain cases our products are held on consignment at a hospital or clinic prior to purchase; in these instances we recognize revenue at the time the product is used in surgery rather than at shipment.

Cost of sales. We manufacture the majority of the products that we sell. Our cost of sales consists primarily of manufacturing personnel, raw materials and components, depreciation of property and equipment, and other allocated manufacturing overhead, as well as the freight expense we pay to ship products to customers.

Sales and marketing. Our sales and marketing expense consists primarily of salaries, commissions, stock-based compensation, travel and entertainment, attendance at vascular congresses, training programs, advertising and product promotions, direct mail and other marketing costs.

General and administrative. General and administrative expense consists primarily of executive, finance and human resource expense, stock-based compensation, legal and accounting fees, acquisition-related charges, information technology expense, intangible asset amortization expense and insurance expense.

Research and development. Research and development expense includes costs associated with the design, development, testing, enhancement and regulatory approval of our products, principally salaries, laboratory testing and supply costs. It also includes costs associated with design and execution of clinical studies, regulatory submissions and costs to register, maintain, and defend our intellectual property, and royalty payments associated with licensed and acquired intellectual property.

Other income (expense). Other income (expense) primarily includes interest income and expense, foreign currency gains (losses), and other miscellaneous gains (losses).

Income tax expense. We are subject to federal and state income taxes for earnings generated in the United States, which include operating losses in certain foreign jurisdictions for certain years depending on tax elections made, and foreign taxes on earnings of our wholly-owned foreign subsidiaries. Our consolidated tax expense is affected by the mix of our taxable income (loss) in the United States and foreign subsidiaries, permanent items, discrete items, unrecognized tax benefits, and amortization of goodwill for U.S. tax reporting purposes.

Table of Contents**Results of Operations****Comparison of the three and nine months ended September 30, 2017 to the three and nine months ended September 30, 2016.**

The following tables set forth, for the periods indicated, our results of operations, net sales by geography, and the change between the specified periods expressed as a percentage increase or decrease:

| (unaudited) | Three months ended September 30, | | | Nine months ended September 30, | | |
|-------------------------|-------------------------------------|-----------|--|------------------------------------|-----------|-------------------|
| | 2017 | 2016 | Percent change (\$ in thousands) | 2017 | 2016 | Percent change |
| Net sales | \$ 24,822 | \$ 23,216 | 7% | \$ 74,714 | \$ 65,863 | 13% |
| Net sales by geography: | | | | | | |
| Americas | \$ 15,442 | \$ 14,528 | 6% | \$ 46,511 | \$ 39,594 | 17% |
| International | 9,380 | 8,688 | 8% | 28,203 | 26,269 | 7% |
| Total | \$ 24,822 | \$ 23,216 | 7% | \$ 74,714 | \$ 65,863 | 13% |

Net sales. Net sales increased \$1.6 million or 7% to \$24.8 million for the three months ended September 30, 2017, compared to \$23.2 million for the three months ended September 30, 2016. Sales increases for the three months ended September 30, 2017 were due in large part to sales of our RestoreFlow service offering (acquired in the fourth quarter of 2016) of \$1.6 million. Other products with increased sales included carotid shunts of \$0.4 million and Omniflow II biosynthetic vascular grafts of \$0.2 million, which were offset by lower sales of valvulotomes of \$0.6 million.

Net sales increased \$8.8 million or 13% to \$74.7 million for the nine months ended September 30, 2017, compared to \$65.9 million for the nine months ended September 30, 2016. Sales increases for the nine months ended September 30, 2017 were due in large part to sales of our RestoreFlow service offering of \$4.4 million. Other products with increased sales included biologic vascular patches of \$2.8 million, carotid shunts of \$0.9 million, Omniflow II biosynthetic vascular grafts of \$0.6 million, and vessel closure systems of \$0.6 million, which were offset by lower sales of valvulotomes of \$0.7 million.

Direct-to-hospital net sales were 93% and 92% for the nine months ended September 30, 2017 and September 30, 2016, respectively.

Net sales by geography. Net sales in the Americas increased \$0.9 million or 6% for the three months ended September 30, 2017. The increase was due in large part to sales of our RestoreFlow service offering of \$1.6 million, and increased sales of carotid shunts of \$0.3 million. These increases were partially offset by lower valvulotome sales of \$0.8 million and biologic vascular patches of \$0.3 million. International net sales for the three months ended September 30, 2017 increased \$0.7 million or 8% due mainly to higher sales of biologic vascular patches of \$0.2 million and valvulotomes of \$0.2 million, as well as carotid shunts, biosynthetic vascular grafts and polyester vascular grafts, each of \$0.1 million.

Net sales in the Americas increased \$6.9 million for the nine months ended September 30, 2017. The increase was due in large part to sales of our RestoreFlow service offering of \$4.4 million, as well as our ProCol biologic grafts of

\$0.4 million. We also recorded increased sales of our biologic vascular patches of \$1.8 million, vessel closure systems of \$0.5 million and carotid shunts of \$0.6 million. These increases were partially offset by lower sales of valvulotomes of \$0.8 million. International net sales for the nine months ended September 30, 2017 increased \$1.9 million, or 7%, due mainly to higher sales of biologic vascular patches, Omniflow II biosynthetic grafts and powered phlebectomy devices, partially offset by decreased sales of catheters and ePTFE vascular grafts.

| (unaudited) | Three months ended September 30, | | | | Nine months ended September 30, | | | |
|--------------|-------------------------------------|-----------|-----------|-------------------|------------------------------------|-----------|-----------|-------------------|
| | 2017 | 2016 | \$ Change | Percent change | 2017 | 2016 | \$ Change | Percent change |
| | (\$ in thousands) | | | | | | | |
| Gross profit | \$ 17,577 | \$ 17,019 | \$ 558 | 3% | \$ 52,446 | \$ 46,742 | \$ 5,704 | 12% |
| Gross margin | 70.8% | 73.3% | * | (2.5%) | 70.2% | 71.0% | * | (0.8%) |

* Not applicable

Table of Contents

Gross Profit. Gross profit increased \$0.6 million to \$17.6 million for the three months ended September 30, 2017, while gross margin decreased by 250 basis points to 70.8%. The gross margin decrease was mainly the result of the addition of our RestoreFlow service offering in November 2016, which carries comparatively lower gross margins than our other products, as well as lower valvulotome sales and an unfavorable geographic mix of our revenues. These factors were offset partially by pricing increases in 2017 as well as the effects of foreign exchange.

Gross profit increased \$5.7 million to \$52.4 million for the nine months ended September 30, 2017, while gross margin decreased by 80 basis points to 70.2% in the period. The gross margin decrease was mainly the result of the addition of our RestoreFlow service offering in November 2016, which carries comparatively lower gross margins than our other products, as well as lower valvulotome sales, which were partially offset by pricing increases, favorable geographic and product mix, and the effects of foreign exchange.

Operating Expenses

Our operating expenses for the three and nine month periods ended September 30, 2017 and 2016 consisted of the following (in thousands):

| (unaudited) | Three months ended September 30, | | | | Nine months ended September 30, | | | |
|----------------------------|-------------------------------------|-----------|-----------|-------------------|------------------------------------|-----------|-----------|-------------------|
| | 2017 | 2016 | \$ Change | Percent change | 2017 | 2016 | \$ Change | Percent change |
| Sales and marketing | \$ 6,201 | \$ 6,541 | \$ (340) | (5%) | \$ 19,754 | \$ 19,353 | \$ 401 | 2% |
| General and administrative | 4,562 | 3,595 | 967 | 27% | 12,857 | 10,343 | 2,514 | 24% |
| Research and development | 1,761 | 1,539 | 222 | 14% | 5,053 | 4,619 | 434 | 9% |
| Total | \$ 12,524 | \$ 11,675 | \$ 849 | 7% | \$ 37,664 | \$ 34,315 | \$ 3,349 | 10% |

| | Three months ended September 30, | | | Nine months ended September 30, | | |
|----------------------------|-------------------------------------|-------------------|--------|------------------------------------|-------------------|--------|
| | 2017 | 2016 | Change | 2017 | 2016 | Change |
| | % of Net Sales | % of Net Sales | | % of Net Sales | % of Net Sales | |
| Sales and marketing | 25% | 28% | (3%) | 26% | 29% | (3%) |
| General and administrative | 18% | 15% | 3% | 17% | 16% | 1% |
| Research and development | 7% | 7% | 0% | 7% | 7% | 0% |

Sales and marketing. Sales and marketing expenses for the three months ended September 30, 2017 decreased \$0.3 million or 5% vs. the September 30, 2016 period. Decreases were mainly driven by a decline in compensation-related costs of \$0.2 million related to fewer direct sales representatives as well as the vacancy in the position of Vice President Sales, The Americas. Sales meeting expense also decreased \$0.1 million due to an event held in the 2016 period that was not held in the 2017 period.

For the nine months ended September 30, 2017, sales and marketing expenses increased \$0.4 million or 2% to \$19.8 million. The increase was primarily driven by increased compensation-related expenses, related to an increase in the average number of sales representatives during the comparative periods, from 91 in 2016 to 93 in 2017. As a

percentage of net sales, sales and marketing expense decreased to 26% in the nine months ended September 30, 2017 from 29% in the prior year period due to higher sales in the current period.

Table of Contents

General and administrative. For the three months ended September 30, 2017, general and administrative expenses increased \$1.0 million or 27% to \$4.6 million. Included in the current period is a charge of \$0.5 million related to a stock option award modification associated with the recent departure of our President of International Operations. We also had higher compensation costs of \$0.2 million, acquisition-related charges of \$0.2 million, and recruiting fees of \$0.1 million.

For the nine months ended September 30, 2017, general and administrative expenses increased \$2.5 million, or 24%, to \$12.9 million. Increases included the aforementioned stock option award modification charge, higher compensation costs of \$0.5 million, acquisition-related charges of \$0.6 million, facility-related costs of \$0.5 million in connection with expanding our Burlington manufacturing operations, and professional service fees of \$0.3 million. As a percentage of net sales, general and administrative expenses increased to 17% for the nine months ended September 30, 2017 as compared to 16% for the year-earlier period.

Research and development. Research and development expenses for the three months ended September 30, 2017 increased \$0.2 million or 14% to \$1.8 million, primarily due to higher professional services and testing costs.

For the nine months ended September 30, 2017, research and development expenses increased \$0.4 million or 9%, to \$5.1 million. Increases were primarily due to higher compensation costs as well as higher product testing expenses related to clinical and regulatory.

Income tax expense. We recorded a tax provision of \$31,000 on pre-tax income of \$5.1 million for the three months ended September 30, 2017, compared to a \$2.1 million tax provision on pre-tax income of \$5.3 million for the three months ended September 30, 2016. We recorded a tax provision of \$1.9 million on pre-tax income of \$14.8 million for the nine months ended September 30, 2017, compared to \$4.4 million on pre-tax income of \$12.4 million for the nine months ended September 30, 2016. Our effective income tax rate was 0.6% and 12.8% for the three and nine month periods ended September 30, 2017. Our tax expense for the current period is based on an estimated annual effective tax rate of 36.8%, adjusted in the applicable quarterly periods for discrete stock option exercises and other discrete items. Our income tax expense for the current period varies from the statutory rate mainly due to certain permanent items, offset by lower statutory rates from our foreign entities and a discrete item for stock option exercises.

Our effective income tax rate was 39.2% and 35.6% for the three and nine month periods ended September 30, 2016. Our 2016 provision was based on the estimated annual effective tax rate of 34.8%, adjusted in the applicable quarterly period for discrete stock option exercises and other discrete items. Our income tax expense for 2016 varied from the statutory rate mainly due to certain permanent items, offset by lower statutory rates from our foreign entities and a discrete item for stock option exercises.

We monitor the mix of profitability by tax jurisdiction and adjust our annual expected rate on a quarterly basis as needed. While it is often difficult to predict the final outcome or timing of the resolution for any particular tax matter, we believe that our tax reserves reflect the probable outcome of known contingencies.

We assess the likelihood that our deferred tax assets will be realized through future taxable income and record a valuation allowance to reduce gross deferred tax assets to an amount we believe is more likely than not to be realized. As of September 30, 2017, we have provided a valuation allowance of \$1.9 million for deferred tax assets primarily related to Australian net operating loss and capital loss carry forwards and Massachusetts tax credit carry forwards that are not expected to be realized.

We expect that our effective tax rate will remain somewhat inconsistent for the remainder of 2017 due to the timing of exercises of certain employee stock options. We expect our 2017 effective tax rate will be lower than our 2016 effective tax rate mainly due to exercises of stock options in 2017.

Table of Contents

Liquidity and Capital Resources

At September 30, 2017, our cash and cash equivalents were \$37.5 million as compared to \$24.3 million at December 31, 2016. Our cash and cash equivalents are highly liquid investments with maturities of 90 days or less at the date of purchase, consist of operating bank accounts and money market funds, and are stated at cost, which approximates fair value. All of our cash held outside of the United States is available for corporate use, with the exception of \$7.8 million held by certain international subsidiaries where earnings are planned to be permanently reinvested.

On July 25, 2016, our Board of Directors approved a stock repurchase program under which the Company was authorized to repurchase up to \$5 million of its common stock through transactions on the open market, in privately negotiated purchases or otherwise. We did not make any repurchases under this program prior to its July 25, 2017 expiration.

On July 25, 2017, our Board of Directors approved a stock repurchase program under which the Company is authorized to repurchase up to \$7.5 million of its common stock through transactions on the open market, in privately negotiated purchases or otherwise. This program may be suspended or discontinued at any time, and expires on the earlier of July 25, 2018 or when the authorized aggregate \$7.5 million repurchase limit is reached, unless extended by our Board of Directors. To date we have not made any repurchases under this program.

Operating and Capital Expenditure Requirements

We require cash to pay our operating expenses, make capital expenditures, and pay our long-term liabilities. Since our inception, we have funded our operations through public offerings and private placements of equity securities, short-term borrowings, and funds generated from our operations.

We recognized operating income of \$14.8 million for the nine months ended September 30, 2017. For the year ended December 31, 2016, we had operating income of \$16.3 million. We expect to fund any increased costs and expenditures from our existing cash and cash equivalents, though our future capital requirements depend on numerous factors. These factors include, but are not limited to, the following:

the revenues generated by sales of our products and services;

payments associated with potential future quarterly cash dividends to our common stockholders;

future acquisition-related payments;

payments associated with income and other taxes;

the costs associated with expanding our manufacturing, marketing, sales, and distribution efforts;

the costs associated with our initiatives to sell direct-to-hospital in new countries;

the costs of obtaining and maintaining FDA and other regulatory clearances of our existing and future products;

the number, timing, and nature of acquisitions and other strategic transactions, and

potential future share repurchases.

Our cash balances may decrease as we continue to use cash to fund our operations, make acquisitions, make payments under our quarterly dividend program, make share repurchases, and make deferred payments related to prior acquisitions. We believe that our cash, cash equivalents, investments and the interest we earn on these balances will be sufficient to meet our anticipated cash requirements for at least the next twelve months. If these sources of cash are insufficient to satisfy our liquidity requirements beyond the next twelve months, we may seek to sell additional equity or debt securities or borrow funds from, or establish a revolving credit facility with a financial institution. The sale of additional equity and debt securities may result in dilution to our stockholders. If we raise additional funds through the issuance of debt securities, such securities could have rights senior to those of our common stock and could contain covenants that would restrict our operations and possibly our ability to pay dividends. We may require additional capital beyond our currently-forecasted amounts. Any such required additional capital may not be available on reasonable terms, if at all.

Table of Contents**Dividends**

In February 2011, our Board of Directors approved a policy for the payment of quarterly cash dividends on our common stock. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by our Board of Directors. The dividend activity for the periods presented is as follows:

| Record Date | Payment Date | Per Share Amount Dividend Payment | |
|-------------------------|---------------------|--|----------------|
| | | | (in thousands) |
| Fiscal Year 2017 | | | |
| March 22, 2017 | April 6, 2017 | \$ 0.055 | \$ 1,029 |
| May 24, 2017 | June 8, 2017 | \$ 0.055 | \$ 1,036 |
| August 23, 2017 | September 6, 2017 | \$ 0.055 | \$ 1,055 |
| Fiscal Year 2016 | | | |
| March 21, 2016 | April 4, 2016 | \$ 0.045 | \$ 825 |
| May 25, 2016 | June 8, 2016 | \$ 0.045 | \$ 829 |
| August 22, 2016 | September 2, 2016 | \$ 0.045 | \$ 833 |
| November 21, 2016 | December 5, 2016 | \$ 0.045 | \$ 836 |

On October 24, 2017 our Board of Directors approved a quarterly cash dividend on our common stock of \$0.055 per share payable on December 7, 2017 to stockholders of record at the close of business on November 22, 2017, which will total approximately \$1.0 million.

Cash Flows

| | Nine months ended September 30, | | |
|-----------------------------------|--|-------------|-------------------|
| | (in thousands) | | |
| | 2017 | 2016 | Net Change |
| Cash and cash equivalents | \$ 37,514 | \$ 34,650 | \$ 2,864 |
| Cash flows provided by (used in): | | | |
| Operating activities | \$ 16,098 | \$ 12,702 | \$ 3,396 |
| Investing activities | (4,780) | (4,198) | (582) |
| Financing activities | 1,146 | (1,535) | 2,681 |

Net cash provided by (used in) operating activities. Net cash provided by operating activities was \$16.1 million for the nine months ended September 30, 2017, consisting of \$12.9 million in net income adjusted for non-cash items of \$5.2 million (including depreciation and amortization of \$3.0 million, stock-based compensation of \$1.8 million, and provisions for inventory write-offs and doubtful accounts of \$0.4 million) and offset by changes in working capital of \$2.0 million. The net cash used for working capital was driven by increases in inventory of \$1.3 million, accounts receivable of \$0.1 million and prepaid expenses and other current assets of \$1.4 million, offset by a decrease in accounts payable and other liabilities of \$0.8 million.

Table of Contents

Net cash provided by operating activities was \$12.7 million for the nine months ended September 30, 2016, and consisted of \$8.0 million net income, adjusted for non-cash items of \$4.2 million (including depreciation and amortization of \$2.7 million, stock-based compensation of \$1.2 million, and provisions for inventory write-offs and doubtful accounts of \$0.3 million), as well as changes in working capital of \$0.5 million. The net cash used by changes in working capital was driven by increases in accounts payable and other liabilities of \$1.2 million offset by decreases in other current assets of \$0.4 million, inventory of \$0.2 million and accounts receivable of \$0.1 million.

Net cash used in investing activities. Net cash used in investing activities was \$4.8 million for the nine months ended September 30, 2017. This was primarily driven by expenditures on leasehold improvements and equipment associated with the expansion of our Burlington facility.

Net cash used in investing activities was \$4.2 million for nine months ended September 30, 2016, driven by \$2.4 million of cash paid in connection with our acquisition of the ProCol biologic vascular grafts, as well as purchases of property and equipment of \$1.8 million primarily associated with the expansion of our Burlington facility

Net cash provided by (used in) financing activities. Net cash provided by financing activities was \$1.1 million for the nine months ended September 30, 2017, consisting of proceeds from stock option exercises of \$5.5 million, offset by dividend payments of \$3.1 million, shares withheld to satisfy employee taxes on restricted stock vesting of \$0.8 million and payments related to prior acquisitions of \$0.4 million.

Net cash used in financing activities was \$1.5 million for the nine months ended September 30, 2016, driven primarily by payments of common stock dividends of \$2.5 million, partially offset by proceeds from stock option exercises, net of shares withheld to satisfy employee taxes on restricted stock vesting of \$1.2 million. We also made payments related to our prior acquisitions of \$0.2 million.

Contractual obligations. Our principal contractual obligations consist of operating leases and inventory purchase commitments, and have not changed significantly since December 31, 2016 as reported in our Annual Report on Form 10-K.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements as of September 30, 2017. We do not currently have, nor have we ever had, any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts. As a result, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in these relationships.

Critical Accounting Policies and Estimates

We have adopted various accounting policies to prepare our consolidated financial statements in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. Our most significant accounting policies are described in note 1 to our consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016. There have been no material changes in our critical accounting policies during the nine months ended September 30, 2017. The preparation of our consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Our estimates and assumptions, including those related to bad debts, inventories, intangible assets, sales returns and discounts, share-based compensation, and income taxes are reviewed on an

ongoing basis and updated as appropriate. Actual results may differ from those estimates.

Table of Contents***Recent Accounting Pronouncements***

In May 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2017-09 which provides guidance on determining which changes to the terms and conditions of share-based payment awards require an entity to apply modification accounting under ASC 718, Compensation – Stock Compensation. The new standard is effective for us beginning January 1, 2018, with early adoption permitted. The adoption of this standard is not expected to have a material impact on our financial statements.

In January 2017, FASB issued ASU 2017-04, which, among other provisions, eliminates step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test will be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit's fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The new standard is effective for us beginning January 1, 2020, with early adoption permitted. The adoption of this standard is not expected to have a material impact on our financial statements.

In January 2017, the FASB issued ASU 2017-01 which changes the definition of a business for purposes of determining whether a business has been acquired or sold. The amendment is intended to help companies evaluate whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new standard is effective for us beginning January 1, 2018, with early adoption permitted. The adoption of this standard is not expected to have a material impact on our financial statements.

In August 2016, the FASB issued ASU 2016-15, which changes the classification of certain cash receipts and cash payments within the statement of cash flows. The new standard is effective for us beginning January 1, 2018, with early adoption permitted. The adoption of this standard is not expected to have a material impact on our financial statements.

In May 2014, the FASB and the International Accounting Standards Board issued substantially converged final standards on revenue recognition. The FASB's ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), as amended from time to time, outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The new revenue recognition guidance becomes effective for us on January 1, 2018, with early adoption permitted on January 1, 2017. Entities have the option of using either a full retrospective or a modified approach to adopt the guidance in the ASU. Our assessment of the impact to our financial statements of adopting this standard is underway. We engaged external consultants to assist us with our analysis, which included evaluating our standard arrangements with customers, as well as arrangements specific to certain customer bases or product offerings, and reviewing a sample of actual contracts to determine whether there are additional attributes to consider beyond our standard arrangements. Although our assessment is not complete, we do not currently expect that adoption of Topic 606 will have a material impact on our consolidated financial statements. However, there will likely be changes to our revenue recognition accounting policy as well as other disclosures.

Additionally, we have preliminarily determined that we will use the modified retrospective method of adoption.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

In the ordinary course of conducting business, we are exposed to certain risks associated with potential changes in market conditions. These market risks include changes in currency exchange rates and interest rates which could

affect operating results, financial position and cash flows. We manage our exposure to these market risks through our regular operating and financing activities and, if considered appropriate, we may enter into derivative financial instruments such as forward currency exchange contracts, although we have not done so in 2017 or in recent years. There have been no material changes in our quantitative and qualitative market risks since the disclosure in our Annual Report on Form 10-K for the year ended December 31, 2016.

Table of Contents

Item 4. Controls and Procedures Evaluation of Disclosure Controls and Procedures

Our management, with the participation and supervision of our Chief Executive Officer and Chief Financial Officer, is responsible for our disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified under SEC rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, management concluded that the company’s internal control over financial reporting was effective as of September 30, 2017. In November 2016, we acquired substantially all of the assets of the RestoreFlow allograft business from Restore Flow Allografts LLC. This acquired business, which during the nine months ended September 30, 2017 comprised 5.9% of our revenues and as of that date comprised approximately 2.5% of our total assets, is excluded from our evaluation of internal control over financial reporting.

Changes in Internal Control

There have been no changes in our internal control over financial reporting for the nine months ended September 30, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Management is in the process of assessing the effectiveness of internal control over financial reporting for the acquired RestoreFlow allograft business.

Inherent Limitations of Internal Controls

Notwithstanding the foregoing, our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any system will succeed in achieving its stated goals under all potential future conditions. Over time, control may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Part II. Other Information

Item 1. Legal Proceedings

In the ordinary course of business, we are from time to time involved in lawsuits, claims, investigations, proceedings, and threats of litigation relating to employment, product liability, commercial arrangements, contracts, intellectual property and other matters. While the outcome of these proceedings and claims cannot be predicted with certainty, there are no matters, as of November 1, 2017, that management believes would have a material adverse effect on our financial position, results of operations or cash flows.

Table of Contents**Item 1A. Risk Factors**

In addition to the information set forth in this report, you should consider the risks and uncertainties discussed in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2016, which could materially affect our business, financial condition, or future results. There have been no substantive changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2016, which was filed with the Securities and Exchange Commission on March 8, 2017.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Recent Sales of Unregistered Securities

None.

Issuer Purchases of Equity Securities

| Period | Issuer Purchases of Equity Securities | | | |
|--|---|--|--|--|
| | Total Number of Shares (or Units) Purchased (1) | Average Price Paid Per Share (or Unit) | Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Program | Maximum Number (or Approximate Dollar Value) of Shares (or Units) that may yet be Purchased under the Plans or Program |
| July 1, 2017 through July 31, 2017 | 27,291 | \$ 28.51 | N/A | N/A |
| August 1, 2017 through August 31, 2017 | | | N/A | N/A |
| September 1, 2017 through September 30, 2017 | | | N/A | N/A |
| Total | 27,291 | \$ 28.51 | N/A | N/A |

- (1) For the three months ended September 30, 2017, we withheld 27,291 shares of common stock to satisfy employees' obligations with respect to minimum statutory withholding taxes in connection with the vesting of restricted stock units.

Table of Contents

Item 6. Exhibits

| Exhibit Number | Exhibit Description | Incorporated by Reference | | | Filed Herewith |
|-------------------|---|---------------------------|------|--------|-------------------|
| | | Form | Date | Number | |
| 31.1 | <u>Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).</u> | | | | X |
| 31.2 | <u>Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).</u> | | | | X |
| 32.1 | <u>Certification by the Chief Executive Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350).*</u> | | | | X |
| 32.2 | <u>Certification by the Chief Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350).*</u> | | | | X |
| 101.INS | XBRL Instance Document. | | | | X |
| 101.SCH | XBRL Taxonomy Extension Schema Document. | | | | X |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document. | | | | X |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document. | | | | X |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document. | | | | X |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document. | | | | X |

+ Indicates a management contract or any compensatory plan, contract, or arrangement.

* The certifications attached as Exhibit 32.1 and Exhibit 32.2 that accompany this Quarterly Report on Form 10-Q, are not deemed filed with the SEC and are not to be incorporated by reference into any filing of LeMaitre Vascular, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on November 3, 2017.

LEMAITRE VASCULAR, INC.

/s/ George W. LeMaitre

George W. LeMaitre

Chairman and Chief Executive Officer

/s/ Joseph P. Pellegrino, Jr.

Joseph P. Pellegrino, Jr.

Chief Financial Officer and Director

Table of Contents**EXHIBIT INDEX**

| Exhibit | Exhibit Description | Incorporated by Reference | | | Filed |
|----------------|--|----------------------------------|-------------|---------------|--------------|
| | | Form | Date | Number | |
| 31.1 | Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a). | | | | X |
| 31.2 | Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a). | | | | X |
| 32.1 | Certification by the Chief Executive Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350).* | | | | X |
| 32.2 | Certification by the Chief Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350).* | | | | X |
| 101.INS | XBRL Instance Document. | | | | X |
| 101.SCH | XBRL Taxonomy Extension Schema Document. | | | | X |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document. | | | | X |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document. | | | | X |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document. | | | | X |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document. | | | | X |

+ Indicates a management contract or any compensatory plan, contract, or arrangement.

* The certifications attached as Exhibit 32.1 and Exhibit 32.2 that accompany this Quarterly Report on Form 10-Q, are not deemed filed with the SEC and are not to be incorporated by reference into any filing of LeMaitre Vascular, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.